Brinker Capital Investments’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Brinker Capital Investments’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-27,000	Closed	-$1.25M	–	334
2020 Q1	$1.25M	Hold	27,000	–	–	0.06%	186
2019 Q4	$1.51M	Sell	27,000 -128,000	-83%	-$6.67M	0.05%	198
2019 Q3	$7.34M	Hold	155,000	–	–	0.25%	91
2019 Q2	$8.3M	Buy	+155,000	New	+$8.04M	0.26%	94
2015 Q2	–	Sell	-420	Closed	-$23K	–	439
2015 Q1	$23K	Buy	+420	New	+$22.7K	﹤0.01%	335

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

ACM

Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Brinker Capital Investments's PBE Position: Q2 2020 in Review

Brinker Capital Investments sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2020, closing a stake of 27,000 shares — an estimated $1.25M sold.

Brinker Capital Investments first reported a position in PBE in Q1 2015 and held it in 5 quarters. The position peaked at $8.3M in Q2 2019. 77 funds tracked by Wall St. Rank hold PBE as of Q2 2020.

Brinker Capital Investments reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2020 after selling out during the quarter.
Brinker Capital Investments sold 27,000 Invesco Biotechnology & Genome ETF shares in Q2 2020, an estimated $1.25M.
Brinker Capital Investments first reported a position in Invesco Biotechnology & Genome ETF in Q1 2015 and held it in 5 quarters.
Brinker Capital Investments's Invesco Biotechnology & Genome ETF position peaked at $8.3M in Q2 2019.
77 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2020.

Based on Brinker Capital Investments's 13F filing for Q2 2020, filed 12 Aug 2020.